Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

CAR-T cell therapy for heart diseases

Description:

 

CAR-T cells targeting cardiac fibroblasts to reduce pathological fibrosis and improve cardiac function

 

Most forms of heart failure are accompanied by cardiac fibrosis causing a “stiff heart” and contractile dysfunction, which most commonly refers to the excessive deposition of extracellular matrix in the cardiac muscle: fibroblasts become activated, resulting in excess matrix deposition and stiffening of the myocardium. No therapies exist to effectively treat or reverse cardiac fibrosis.

 

Drs. Epstein and Aghajanian tested whether targeting activated cardiac fibroblasts could reduce fibrosis and improve heart function.

 

In a mouse model, engineered T cells targeting Fibroblast Activation Protein (FAP) expressed by activated fibroblasts in the heart are effective at reducing cardiac fibrosis and improving heart function in hypertensive-associated heart failure.

 

 

FAP CAR T cells can target cardiac fibrosis:

 

 

a. Schematic of experiments for FAP CAR T cell targeting of cardiac fibroblasts. C57BL/6 mice were continuously administered AngII/PE through an osmotic minipump to induce cardiac injury and fibrosis. FAP CAR T cells were adoptively transferred 1 and 2 weeks after pump implantation when fibrosis had already been established. Mice were evaluated and euthanized at 4 weeks to assess fibrosis.

b. Top, Picro-Sirius red staining of heart coronal sections in mice treated with saline (left), AngII/PE (centre) or AngII/PE and FAP CAR T cells (right) to evaluate fibrosis (red). Bottom, magnification of left ventricular fibrosis. Scale bar, 100 μm.

c. Quantification of cardiac fibrosis.

d. Comparison of cardiac functional parameters and body weight between experimental and control groups.

e. M mode echocardiography of mice treated with saline (top), AngII/PE (middle) or AngII/PE and FAP CAR T cells

(bottom). Arrows indicate systole and diastole and highlight the difference. Representative images of two independent experiments, showing similar results

 

Applications:

 

•       Treatment of cardiac fibrosis

 

Advantages:

 

•       Broadly applicable in range of heart diseases related to cardiac fibrosis

•       Minimal off-target effects observed

 

Stage of Development:

 

•       Target identified

•       Preclinical discovery

 

Intellectual Property:

 

•       WO2019067425A1

 

Reference Media:

 

•       Nature, 2019, 573 (430-433)

•       Penn Medicine News

 

Desired Partnerships:

 

•       License

•       Co-development

 

Docket: 18-8420

 


Patent Information:
For Information, Contact:
Viviane Martin
Director, PSOM Licensing Group
University of Pennsylvania
215-746-4275
martinv@upenn.edu
Inventors:
Haig Aghajanian
Jonathan Epstein
Keywords: